Publication:
Antibiotic susceptibility of clinical burkholderia pseudomallei isolates in northeast thailand from 2015 to 2018 and the genomic characterization of β-lactam-resistant isolates

dc.contributor.authorShirley Yi Fen Hiien_US
dc.contributor.authorSarunporn Tandhavananten_US
dc.contributor.authorRungnapa Phunpangen_US
dc.contributor.authorPeeraya Ekchariyawaten_US
dc.contributor.authorNatnaree Saipromen_US
dc.contributor.authorClaire Chewapreechaen_US
dc.contributor.authorRathanin Sengen_US
dc.contributor.authorEkkachai Thiansukhonen_US
dc.contributor.authorChumpol Morakoten_US
dc.contributor.authorNarongchai Sangsaen_US
dc.contributor.authorSunee Chayangsuen_US
dc.contributor.authorSomchai Chuananonten_US
dc.contributor.authorKittisak Tanwisaiden_US
dc.contributor.authorWirayut Silakunen_US
dc.contributor.authorNoppol Buasien_US
dc.contributor.authorSeksan Chaisuksanten_US
dc.contributor.authorTanin Hompleumen_US
dc.contributor.authorPloenchan Chetchotisakden_US
dc.contributor.authorNicholas P.J. Dayen_US
dc.contributor.authorWasun Chantratitaen_US
dc.contributor.authorGanjana Lertmemongkolchaien_US
dc.contributor.authorT. Eoin Westen_US
dc.contributor.authorNarisara Chantratitaen_US
dc.contributor.otherRamathibodi Hospitalen_US
dc.contributor.otherFaculty of Tropical Medicine, Mahidol Universityen_US
dc.contributor.otherUdon Thani Center Hospitalen_US
dc.contributor.otherFaculty of Medicine, Khon Kaen Universityen_US
dc.contributor.otherSurin Hospitalen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherKhon Kaen Regional Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Medicineen_US
dc.contributor.otherKing Mongkut's University of Technology Thonburien_US
dc.contributor.otherWellcome Sanger Instituteen_US
dc.contributor.otherHarborview Medical Centeren_US
dc.contributor.otherBuriram Hospitalen_US
dc.contributor.otherSisaket Hospitalen_US
dc.contributor.otherRoi Et Hospitalen_US
dc.contributor.otherNakhon Phanom Hospitalen_US
dc.contributor.otherMukdahan Hospitalen_US
dc.date.accessioned2022-08-04T09:25:30Z
dc.date.available2022-08-04T09:25:30Z
dc.date.issued2021-05-01en_US
dc.description.abstractMelioidosis is an often fatal infection in tropical regions caused by an environmental bacterium, Burkholderia pseudomallei. Current recommended melioidosis treatment requires intravenous β-lactam antibiotics such as ceftazidime (CAZ), meropenem (MEM), or amoxicillin-clavulanic acid (AMC) and oral trimethoprim-sulfamethoxazole. Emerging antibiotic resistance could lead to therapy failure and high mortality. We performed a prospective multicenter study in northeast Thailand from 2015 to 2018 to evaluate antibiotic susceptibility and characterize β-lactam resistance in clinical B. pseudomallei isolates. A collection of 1,317 B. pseudomallei isolates from patients with primary and relapse infections were evaluated for susceptibility to CAZ, imipenem (IPM), MEM, and AMC. β-Lactam-resistant isolates were confirmed by the broth microdilution method and characterized by whole-genome sequence analysis, penA expression, and β-lactamase activity. The resistant phenotype was verified via penA mutagenesis. All primary isolates were IPM susceptible, but we observed two CAZ-resistant isolates and one CAZ-intermediate isolate, two MEMCitation less-susceptible isolates, and one AMC-resistant and two AMC-intermediate isolates. One of 13 relapse isolates was resistant to both CAZ and AMC. Two isolates were MEM less susceptible. Strains DR10212A (primary) and DR50054E (relapse) were multidrug resistant. Genomic and mutagenesis analyses supplemented with gene expression and β-lactamase analyses demonstrated that the CAZ-resistant phenotype was caused by PenA variants: P167S (n = 2) and penA amplification (n = 1). Despite the high mortality rate in melioidosis, our study revealed that B. pseudomallei isolates had a low frequency of β-lactam resistance caused by penA alterations. Clinical data suggest that resistant variants may emerge in patients during antibiotic therapy and may be associated with a poor response to treatment.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.65, No.5 (2021)en_US
dc.identifier.doi10.1128/AAC.02230-20en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-85105098806en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/78246
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105098806&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleAntibiotic susceptibility of clinical burkholderia pseudomallei isolates in northeast thailand from 2015 to 2018 and the genomic characterization of β-lactam-resistant isolatesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105098806&origin=inwarden_US

Files

Collections